Novartis

= Novartis =

General Information
toc
 * ~ Company Name || Novartis ||
 * ~ Year founded || 1996 ||
 * ~ Headquarters || Basel, Switzerland ||
 * ~ Number of Locations || 140 ||
 * ~ Key People || Daniel Vasella, CEO and Chairman of the Board of Directors ||
 * = **Net Income** || 10 267 USD million ||
 * = **Operation Income** || 11 437 USD million ||
 * = **Revenue** || 44 267 USD million ||
 * = **Employees** || Approximatelly 100 000 ||
 * = **website** || www.novartis.com ||

Novartis is one of the world leaders in innovative healthcare products. It was created from the merger between Ciba-Geigy and Sandoz, in 1996. Although its main focus has been developing chemical based pharmaceuticals, throughout the years Novartis has been acquiring several biotechnological companies, therefore expanding the research in the biotechnology field. In 2007, Novartis created a biologics unit, which is divided into three of the four different platforms: Sandoz, Vaccines and Diagnostics and Pharmaceuticals.

History

 * **1758 -** Foundation of Geigy
 * **1884** – Foundation of Ciba
 * **1886** – Foundation of Sandoz
 * **1970** – Merge between Ciba and Geigy, creating Ciba-Geigy
 * **1996** – Merge between Ciba-Geigy and Sandoz, forming Novartis
 * **1996 – 2001**
 * Novartis entered the New York Stock Exchange (NYSE)
 * Establishment of the Novartis Institute for Functional Genomics
 * **2002** -
 * Investment in Roche Holding AG, with 32% of Roche’s voting shares
 * Acquisition of Lek Pharmaceuticals by Sandoz
 * Creation of the Novartis Institutes for Biomedical Research (NIBR)
 * **2003** - Acquisition of a majority interest of Idenix Pharmaceuticals
 * **2004** -
 * Opening of the Novartis Institute for Tropical Disease, in Singapore
 * Acquisition of Durasacan A/S and Sabex Holdings Lda., two generic companies
 * Sandoz is named as a division of the Novartis Group
 * **2005** -
 * Acquisition of Hexal AG, a leading generics company
 * Acquisition of the North American OTC brand portfolio
 * Acquisition of Chiron Corporation
 * **2006** - Creation of a R&D center in Xangai, China
 * **2007** - Partnership with Intercell, a biotechnology company

Products

 * **Xolair** - Monoclonal antibody - novel approach for the treatment of moderate to severe allergic asthma.
 * **Simulect -** Monoclonal antibody for induction therapy in kidney transplantation.
 * **Ilaris** – Monoclonal antibody for interleukin 1-beta blockage, switching off the symptoms of inflammation in CAPS patients.
 * **Binocrit** - **(Epoetin alfa)** - First glycoprotein biosimilar approved in any highly regulated country, approved for treatment of anemia.

Financial Information
2009 data of Novartis net sales, R&D spending and number of full-time associates. (*)Corporate data missing .
 * **2009** || **Net sales**
 * (USD million)** || **R & D spending**
 * (USD million)** || **Full-time associates** ||
 * **Total (*)** || 44 267 || 7 307(*) || 97 688(*) ||
 * **Pharmaceuticals** || 28 538 || 5 840 || 56 310 ||
 * **Vaccines and Diagnostics** || 2 424 || 508 || 5 416 ||
 * **Sandoz** || 7 493 || 613 || 23 423 ||
 * **Consumer Health** || 5 812 || 346 || 12 539 ||

The BioValley area
Novartis is an integrating part of BioValley, a region located between three countries: Switzerland, France and Germany. This initiative aims to encourage the founding of new companies and the creation of new and innovative jobs in life sciences/biotechnology. This program is co-funded by the German, Swiss and French governements and by the European Union.



Cláudia Miranda 66805

include component="tagCloud"